© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to September
oral PARP1-DNA selective trapper
1 mpk QD in PDX model, phase I/II, cancer
from literature starting point
Journal of Medicinal Chemistry
The AstraZeneca PARP1-DNA trapper, AZD5305, is a phase I candidate (NCT04644068) for cancer that is selective for PARP1 over PARP2 (>500x). Their study began by profiling the existing clinical and late-stage…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.